Navigation Links
SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
Date:1/6/2009

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has been awarded U.S. Patent number 7,469,160 for its methods and apparatus for evaluating image focus.

Jim Hitchin, SpectraScience's CEO, commented, "This patent is another important addition to our expanding intellectual property portfolio."

The invention provides methods of focusing an instrument for the acquisition of optical data from a tissue sample. It allows rapid focusing in a diagnostic procedure in which quick data acquisition is desirable. For example, the techniques allow a user to focus an optical instrument quickly enough to obtain data within an optimal window of time. In one version, a user focuses an optical instrument by aligning laser spots projected onto a tissue sample within rings that are superimposed at predetermined locations within the user's visual field. The invention further allows automatic validation to detect whether the spots are sufficiently well-aligned.

Hitchin added, "Accurate data acquisition and fast focusing techniques are critical for earlier and more effective identification of normal, pre-cancerous or cancerous tissue. This invention will make our screening devices more useful to the physician and, more importantly, more effective for the patient. It allows the LUMA Cervical Imaging System to detect close to 30% more ASCUS/LSIL cervical cancer precursors than colposcopy alone, providing clinicians with a valuable tool in the fight against cervical cancer. In fact, a recent large-scale National Cancer Institute-sponsored clinical trial demonstrated that colposcopy failed to detect 33% of high-grade precancerous lesions in women referred with questionable Pap results."

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending for its WavSTAT(R) Optical Biopsy and LUMA(R) Cervical Imaging Systems. These non-invasive optical devices are used to diagnose tissue quickly to determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

    Contact:
    SpectraScience, Inc.
    Jim Hitchin, Chief Executive Officer
    (858) 847-0200 x201

    Hayden Communications
    Investor Relations
    Todd Pitcher
    (858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Awarded U.S. Patent 7,459,696 for its Unique Methods of Calibrating Spectral Data
2. SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis
3. SpectraScience Announces Updates
4. SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
5. SpectraScience Awarded Patent for Correcting Image Misalignment
6. SpectraScience Adds Industry Veteran to Executive Team
7. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
8. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
9. SpectraScience, Inc. Retains Hayden Communications
10. SpectraScience Acquires Luma Imaging Corporation
11. SpectraScience Receives Final European Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: